@Biocartis_

Rudi Mariën

Chairman, Non-Executive Director

Rudi Mariën is a non-executive director of Biocartis. He is also President and Managing Director of Gengest BVBA and Biovest Comm.VA. He was the Vice President of Cerba European Lab. Through his management company, Gengest BVBA, Mr. Mariën has board mandates in different listed and private biotech companies. Mr. Mariën was co-founder, reference shareholder and Chairman of Innogenetics, and has been the founder, shareholder and Managing Director of several clinical reference laboratories including the Barc Group, a leading international centralized clinical laboratory, exclusively dedicated to pharmaceutical studies. Mr. Mariën holds a degree in pharmaceutical sciences from the University of Ghent, Belgium and a degree in clinical biology from the University of Ghent, Belgium.

Rudi Mariën

Chairperson

Rudi Mariën is a non-executive director of Biocartis. He is also President and Managing Director of Gengest BVBA and Biovest Comm.VA. He was the Vice President of Cerba European Lab. Through his management company, Gengest BVBA, Mr. Mariën has board mandates in different listed and private biotech companies. Mr. Mariën was co-founder, reference shareholder and Chairman of Innogenetics, and has been the founder, shareholder and Managing Director of several clinical reference laboratories including the Barc Group, a leading international centralized clinical laboratory, exclusively dedicated to pharmaceutical studies. Mr. Mariën holds a degree in pharmaceutical sciences from the University of Ghent, Belgium and a degree in clinical biology from the University of Ghent, Belgium.

Renaat Berckmoes

Chairperson

Renaat Berckmoes is an independent director of Biocartis. He is also a non-executive director at Primacom AG and FPIM-SFPI and a partner at Fortino CVA. Mr. Berckmoes also has held finance positions at Telenet, being CFO from 2006 to 2013. Mr. Berckmoes holds a Master in Business Economics and a Master in Maritime Economics from the University of Antwerp, Belgium and a Master in Political & Social Sciences from the Katholieke Universiteit Leuven, Belgium. 

Rudi Pauwels

Chair of Strategy Committee, Non-executive director

Rudi Pauwels founded Biocartis in 2007 and currently is a member of the Board of Director where he acts as Chairman of the Strategy Committee. As a serial entrepreneur, he also co-founded several other European biotech companies, including Tibotec, Virco and Galapagos Genomics. Throughout his career, he has been driven by his relentless passion to find breakthrough medical solutions, focusing on unmet needs that improve the health outcome for the patient. Enabling worldwide access to personalized medicine for every patient, focused on a more tailored genetic profiling, has been a central theme - whether it is from a treatment or diagnostics point of view. Starting his career as a researcher at the internationally renowned Rega Institute for Medical Research in Leuven (Belgium), Mr. Pauwels has focused for more than two decades on the search and development of anti-HIV drugs and diagnostic tools that enable personalized HIV treatment, a number of which have been approved and introduced in the clinic while generating several billion USD revenue.

With Biocartis, he is today revolutionizing molecular diagnostics with a new generation of high precision diagnostic solutions in oncology and infectious diseases, easily accessible on a global scale, and as such enable better and faster access to new, more personalized treatments for patients. Mr. Pauwels is (co)-author or more than 150 papers in peer-reviewed journals and is the recipient of several awards for his scientific and entrepreneurial accomplishments. Mr. Pauwels holds a PhD in Pharmaceutical Sciences from the Katholieke Universiteit Leuven, Belgium.

Renaat Berckmoes

Committee Member

Renaat Berckmoes is an independent director of Biocartis. He is also a non-executive director at Primacom AG and FPIM-SFPI and a partner at Fortino CVA. Mr. Berckmoes also has held finance positions at Telenet, being CFO from 2006 to 2013. Mr. Berckmoes holds a Master in Business Economics and a Master in Maritime Economics from the University of Antwerp, Belgium and a Master in Political & Social Sciences from the Katholieke Universiteit Leuven, Belgium.

Rudi Mariën

Committee Member

Rudi Mariën is a non-executive director of Biocartis. He is also President and Managing Director of Gengest BVBA and Biovest Comm.VA. He was the Vice President of Cerba European Lab. Through his management company, Gengest BVBA, Mr. Mariën has board mandates in different listed and private biotech companies. Mr. Mariën was co-founder, reference shareholder and Chairman of Innogenetics, and has been the founder, shareholder and Managing Director of several clinical reference laboratories including the Barc Group, a leading international centralized clinical laboratory, exclusively dedicated to pharmaceutical studies. Mr. Mariën holds a degree in pharmaceutical sciences from the University of Ghent, Belgium and a degree in clinical biology from the University of Ghent, Belgium.

Hilde Windels

CEO (ad interim), Director

Hilde Windels, Msc. (F) is CEO (ad interim) of Biocartis. She has close to 20 years of experience in biotech with a track record of building and structuring organizations, private fundraising, M&A, public capital markets and business and corporate strategy. From Sept 2015 until March 2017, she was Deputy CEO for Biocartis. From 2011 until Sept 2015, she was Biocartis’ CFO. From 2009 to mid-2011, she worked as independent CFO for several private biotech companies. From 1999 to 2008, Mrs. Windels was CFO of publicly-listed Devgen. She also served on the boards of Devgen, MDxHealth and FlandersBio and currently is a member of board of Erytech and VIB. Mrs. Windels holds a Masters in Economics (commercial engineer) from the University of Leuven, Belgium.

Mark Shaffar

Committee Member

Mark Shaffar is an independent director of Biocartis. He has 38 years of experience in the biotechnology sector, having held numerous positions at Abbott Laboratories from 1977 to 2014, including Divisional Vice-President of Acquisitions and Licensing. Mr. Shaffar holds an MM in Management Policy, Finance from Northwestern University—Kellogg Graduate School of Management, the United States and a BS in Biochemistry the University of Wisconsin-Madison, the United States.

Mark Shaffar

Committee Member

Mark Shaffar is an independent director of Biocartis. He has 38 years of experience in the biotechnology sector, having held numerous positions at Abbott Laboratories from 1977 to 2014, including Divisional Vice-President of Acquisitions and Licensing. Mr. Shaffar holds an MM in Management Policy, Finance from Northwestern University—Kellogg Graduate School of Management, the United States and a BS in Biochemistry the University of Wisconsin-Madison, the United States.

Mark Shaffar

Independent Director

Mark Shaffar is an independent director of Biocartis. He has 38 years of experience in the biotechnology sector, having held numerous positions at Abbott Laboratories from 1977 to 2014, including Divisional Vice-President of Acquisitions and Licensing. Mr. Shaffar holds an MM in Management Policy, Finance from Northwestern University—Kellogg Graduate School of Management, the United States and a BS in Biochemistry the University of Wisconsin-Madison, the United States.

Roald Borré

Committee Member

Roald Borré is a non-executive director of Biocartis. Mr. Borré started his professional career at the Financieel Economische Tijds newspaper as a financial analyst specialized in high-tech companies, particularly in the ICT and biotech fields. He was responsible for the launch of Wall Street Invest, a weekly with a focus on Nasdaq-listed (mainly) biotech and ICT companies. In 1999, he joined Puilaecto Private Bankers as Senior Fund Manager, where he was in charge of the Biotechnology Fund and managed various investments in the therapeutics and diagnostics field, a position he held until 2006. In 2011, after five years as an entrepreneur, Mr. Borré joined the ParticipatieMaatschappij Vlaanderen as Business and Fund Manager of the TINA fund that focuses on industrial projects with a high degree of innovation and the potential to transform, now adding co-Head of Venture Capital and permanent representative of PMV NV, statutory manager of PMV-TINA Comm.VA to his responsibilities. He is on the board of different TINA portfolio companies and a member of several advisory boards. Mr. Borré holds a Master in Financial and Commercial Sciences (specialisation Accountancy) from EHSAL Management School, Belgium.

Roald Borré

Non-Executive Director

Roald Borré is a non-executive director of Biocartis. Mr. Borré started his professional career at the Financieel Economische Tijds newspaper as a financial analyst specialized in high-tech companies, particularly in the ICT and biotech fields. He was responsible for the launch of Wall Street Invest, a weekly with a focus on Nasdaq-listed (mainly) biotech and ICT companies. In 1999, he joined Puilaecto Private Bankers as Senior Fund Manager, where he was in charge of the Biotechnology Fund and managed various investments in the therapeutics and diagnostics field, a position he held until 2006. In 2011, after five years as an entrepreneur, Mr. Borré joined the ParticipatieMaatschappij Vlaanderen as Business and Fund Manager of the TINA fund that focuses on industrial projects with a high degree of innovation and the potential to transform, now adding co-Head of Venture Capital and permanent representative of PMV NV, statutory manager of PMV-TINA Comm.VA to his responsibilities. He is on the board of different TINA portfolio companies and a member of several advisory boards. Mr. Borré holds a Master in Financial and Commercial Sciences (specialisation Accountancy) from EHSAL Management School, Belgium.

Renaat Berckmoes

Independent Director

Renaat Berckmoes is an independent director of Biocartis. He is also a non-executive director at Primacom AG and FPIM-SFPI and a partner at Fortino CVA. Mr. Berckmoes also has held finance positions at Telenet, being CFO from 2006 to 2013. Mr. Berckmoes holds a Master in Business Economics and a Master in Maritime Economics from the University of Antwerp, Belgium and a Master in Political & Social Sciences from the Katholieke Universiteit Leuven, Belgium.

Peter Piot

Independent Director

Peter Piot is an independent director of Biocartis. He is also Director at the London School of Hygiene & Tropical Medicine. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations from 1995 until 2008, and was an Associate Director of the Global Programme on AIDS of the WHO. Under his leadership, UNAIDS became the chief advocate for worldwide action against AIDS, also spear heading UN reform by bringing together 10 UN systems organizations. In 1976 he co-discovered the Ebola virus in Zaïre. Mr. Piot also led research on HIV/AIDS, sexually transmitted diseases and women’s health and has held positions as professor of microbiology and of public health at various institutions. Mr. Piot has received numerous scientific and civil awards and has published over 550 scientific articles and 16 books. He holds amongst others an M.D. from the University of Ghent, Belgium, a Ph.D. in Microbiology from the University of Antwerp, Belgium and a Diploma of Tropical Medicine from the Antwerp Institute of Tropical Medicine, Belgium.

Rudi Pauwels

Chair of Strategy Committee, Non-executive director

Rudi Pauwels founded Biocartis in 2007 and currently is a member of the Board of Director where he acts as Chairman of the Strategy Committee. As a serial entrepreneur, he also co-founded several other European biotech companies, including Tibotec, Virco and Galapagos Genomics. Throughout his career, he has been driven by his relentless passion to find breakthrough medical solutions, focusing on unmet needs that improve the health outcome for the patient. Enabling worldwide access to personalized medicine for every patient, focused on a more tailored genetic profiling, has been a central theme - whether it is from a treatment or diagnostics point of view. Starting his career as a researcher at the internationally renowned Rega Institute for Medical Research in Leuven (Belgium), Mr. Pauwels has focused for more than two decades on the search and development of anti-HIV drugs and diagnostic tools that enable personalized HIV treatment, a number of which have been approved and introduced in the clinic while generating several billion USD revenue.

With Biocartis, he is today revolutionizing molecular diagnostics with a new generation of high precision diagnostic solutions in oncology and infectious diseases, easily accessible on a global scale, and as such enable better and faster access to new, more personalized treatments for patients. Mr. Pauwels is (co)-author or more than 150 papers in peer-reviewed journals and is the recipient of several awards for his scientific and entrepreneurial accomplishments. Mr. Pauwels holds a PhD in Pharmaceutical Sciences from the Katholieke Universiteit Leuven, Belgium.

Hilde Windels

CEO (ad interim), Director

Hilde Windels, Msc. (F) is CEO (ad interim) of Biocartis. She has close to 20 years of experience in biotech with a track record of building and structuring organizations, private fundraising, M&A, public capital markets and business and corporate strategy. From Sept 2015 until March 2017, she was Deputy CEO for Biocartis. From 2011 until Sept 2015, she was Biocartis’ CFO. From 2009 to mid-2011, she worked as independent CFO for several private biotech companies. From 1999 to 2008, Mrs. Windels was CFO of publicly-listed Devgen. She also served on the boards of Devgen, MDxHealth and FlandersBio and currently is a member of board of Erytech and VIB. Mrs. Windels holds a Masters in Economics (commercial engineer) from the University of Leuven, Belgium.

Hilde Eylenbosch

Chief Commercial Officer, Director

Hilde Eylenbosch is a Senior Business Executive with over 25 years of experience in marketing, product innovation, cross functional businesses and organisational leadership in the life sciences industry. Over the last 5 years, she held the roles of Chief Commercial Officer at Alere Inc and was President of Alere International reporting to the COO. Hilde Eylenbosch holds a degree as Medical Doctor (University of Ghent, Belgium) and  successfully completed the General Management Program at Harvard Business School.

Contact IR

Biocartis Group NV

+32 15 632 600 / IR@biocartis.com